These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 25801635)
1. A new chance to beat diabetic kidney disease: innate immunity and MCP-1: a matter of good and bad macrophages? Gnudi L Nephrol Dial Transplant; 2015 Apr; 30(4):525-7. PubMed ID: 25801635 [No Abstract] [Full Text] [Related]
2. Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy. Boels MGS; Koudijs A; Avramut MC; Sol WMPJ; Wang G; van Oeveren-Rietdijk AM; van Zonneveld AJ; de Boer HC; van der Vlag J; van Kooten C; Eulberg D; van den Berg BM; IJpelaar DHT; Rabelink TJ Am J Pathol; 2017 Nov; 187(11):2430-2440. PubMed ID: 28837800 [TBL] [Abstract][Full Text] [Related]
3. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Chow FY; Nikolic-Paterson DJ; Ozols E; Atkins RC; Rollin BJ; Tesch GH Kidney Int; 2006 Jan; 69(1):73-80. PubMed ID: 16374426 [TBL] [Abstract][Full Text] [Related]
4. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Tesch GH Am J Physiol Renal Physiol; 2008 Apr; 294(4):F697-701. PubMed ID: 18272603 [TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression. Zheng M; Ye S; Zhai Z; Chen Y; Li X; Yang G; Fan A; Wang Y J Diabetes Complications; 2009; 23(2):124-9. PubMed ID: 18413206 [TBL] [Abstract][Full Text] [Related]
6. Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages. Conrad SM; Strauss-Ayali D; Field AE; Mack M; Mosser DM Infect Immun; 2007 Feb; 75(2):653-65. PubMed ID: 17088347 [TBL] [Abstract][Full Text] [Related]
7. Effect of retinoic acid in experimental diabetic nephropathy. Han SY; So GA; Jee YH; Han KH; Kang YS; Kim HK; Kang SW; Han DS; Han JY; Cha DR Immunol Cell Biol; 2004 Dec; 82(6):568-76. PubMed ID: 15550114 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous activation of innate and adaptive immunity participates in the development of renal injury in a model of heavy proteinuria. Faustino VD; Arias SCA; Ferreira Ávila V; Foresto-Neto O; Zambom FFF; Machado FG; Machado Dos Reis L; Malheiros DMAC; Volpini RA; Camara NOS; Zatz R; Fujihara CK Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914975 [TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration. Lv SS; Liu G; Wang JP; Wang WW; Cheng J; Sun AL; Liu HY; Nie HB; Su MR; Guan GJ Int Immunopharmacol; 2013 Oct; 17(2):275-82. PubMed ID: 23791972 [TBL] [Abstract][Full Text] [Related]
11. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Amann B; Tinzmann R; Angelkort B Diabetes Care; 2003 Aug; 26(8):2421-5. PubMed ID: 12882873 [TBL] [Abstract][Full Text] [Related]
12. Targeting the MCP-1/CCR2 System in diabetic kidney disease. Giunti S; Barutta F; Perin PC; Gruden G Curr Vasc Pharmacol; 2010 Nov; 8(6):849-60. PubMed ID: 20180766 [TBL] [Abstract][Full Text] [Related]
13. Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease. Wu L; Li XQ; Chang DY; Zhang H; Li JJ; Wu SL; Zhang LX; Chen M; Zhao MH Nephrol Dial Transplant; 2020 Feb; 35(2):291-297. PubMed ID: 30357416 [TBL] [Abstract][Full Text] [Related]
14. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Wada T; Furuichi K; Sakai N; Iwata Y; Yoshimoto K; Shimizu M; Takeda SI; Takasawa K; Yoshimura M; Kida H; Kobayashi KI; Mukaida N; Naito T; Matsushima K; Yokoyama H Kidney Int; 2000 Oct; 58(4):1492-9. PubMed ID: 11012884 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Trained Innate Immunity in oxLDL Primed Human Coronary Smooth Muscle Cells. Schnack L; Sohrabi Y; Lagache SMM; Kahles F; Bruemmer D; Waltenberger J; Findeisen HM Front Immunol; 2019; 10():13. PubMed ID: 30728822 [No Abstract] [Full Text] [Related]
16. Immunohistochemical study of monocyte chemoattractant protein-1 in the pancreas of NOD mice following cyclophosphamide administration and during spontaneous diabetes. Bai Y; Robinson E; Chai R; Ross JM; Reddy S J Mol Histol; 2006 May; 37(3-4):101-13. PubMed ID: 17063385 [TBL] [Abstract][Full Text] [Related]
17. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Eardley KS; Zehnder D; Quinkler M; Lepenies J; Bates RL; Savage CO; Howie AJ; Adu D; Cockwell P Kidney Int; 2006 Apr; 69(7):1189-97. PubMed ID: 16609683 [TBL] [Abstract][Full Text] [Related]
18. Activation of innate immunity by 14-3-3 ε, a new potential alarmin in osteoarthritis. Millerand M; Sudre L; Nefla M; Pène F; Rousseau C; Pons A; Ravat A; André-Leroux G; Akira S; Satoh T; Berenbaum F; Jacques C Osteoarthritis Cartilage; 2020 May; 28(5):646-657. PubMed ID: 32173627 [TBL] [Abstract][Full Text] [Related]
19. Innate lymphoid cells in kidney diseases. Wang R; Wang Y; Harris DCH; Cao Q Kidney Int; 2021 May; 99(5):1077-1087. PubMed ID: 33387602 [TBL] [Abstract][Full Text] [Related]
20. IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. Yoo JK; Kwon H; Khil LY; Zhang L; Jun HS; Yoon JW J Immunol; 2005 Dec; 175(12):8280-6. PubMed ID: 16339568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]